Assay News and Research

RSS

Scientists identify new markers for obesity treatment

Would you be more likely to try a diet and exercise regimen if you knew in advance if it would actually help you lose weight? Thanks to a new report published in the June 2013 issue of The FASEB Journal, this could become a reality.

31 May 2013

Chromatrap® ChIP assay kit enriches epigenetic marks from primary human tissue cells

A new application note from Porvair Sciences details a protocol for its Chromatrap® ChIP assay kit that has been developed to enrich epigenetic marks from primary human tissue cells.

From Chromatrap® - Porvair Sciences Ltd 28 May 2013

Lab-based skin test eliminates risk of adverse reactions to new drugs, cosmetics

A simple lab-based skin test which eliminates the risk of adverse reactions to new drugs, cosmetics and household chemicals has been developed by a Newcastle University, UK team.

28 May 2013

TSRI scientists devise new technique to find therapeutic antibodies

Scientists at The Scripps Research Institute have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are already used in many of the world's best-selling medicines, diagnostics and laboratory reagents.

24 May 2013

Novel multiplex immunoassay approach to capture HIV antibodies

Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies and can measure even small amounts of multiple antibodies at one time.

24 May 2013

FDA approves Tina-quant HbA1cDx assay for diagnosis of diabetes

Today the U.S. Food and Drug Administration announced that it is allowing marketing of the COBAS INTEGRA 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay) for the diagnosis of diabetes by health care professionals.

24 May 2013

Researchers use new analysis method to determine genes that result in cell death

Lethal and rescuer genes are defined as genes that when inactivated result in cell death or enhanced cell growth, respectively. The ability to identify these genes in large-scale automated screening campaigns could lead to the discovery of valuable new drug targets.

17 May 2013

Previstage GCC Colorectal Cancer Staging Test study to be presented at 2013 ASCO Annual Meeting

DiagnoCure Inc., today announced that results from a large validation study of the PrevistageTM GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology Annual Meeting, taking place in Chicago, Illinois from May 31 to June 4, 2013.

16 May 2013

Researchers identify clue to explain the reversible memory loss caused by statins

The U.S. Food and Drug Administration and physicians continue to document that some patients experience fuzzy thinking and memory loss while taking statins, a class of global top-selling cholesterol-lowering drugs.

13 May 2013

New diagnostic test could help health officials monitor, prevent spread of H7N9 virus

Breaking research appearing online today in Clinical Chemistry, the journal of AACC, demonstrates that a recently developed diagnostic test can detect the new strain of influenza (H7N9) currently causing an outbreak in China.

13 May 2013

Abbott receives CE Mark for ARCHITECT HbA1c test

Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.

9 May 2013

Precision Therapeutics to present clinical data of ChemoFx chemoresponse assay at WAGO meeting

Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.

9 May 2013

UCSF researchers find new genomic test to identify aggressive form of prostate cancer

A new genomic test for prostate cancer can help predict whether men are more likely to harbor an aggressive form of the disease, according to a new UC San Francisco study.

9 May 2013

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited.

8 May 2013

Novel screening method for identifying inhibitors of EZH2 methyltransferase

Tumor repressor genes, which inhibit tumor formation, can be "turned off" due to undesirable molecular changes affecting the chromosomes on which the genes reside. Understanding and being able to control these alterations could lead to new approaches for activating or inactivating genes linked to cancer.

5 May 2013

Measurement variation influences gene expression profiles of breast cancer

An important new study has revealed the clearest picture yet of precisely how much measurement variation influences gene expression profiles of breast cancer.

3 May 2013

Researchers find association between DCIS Score and risk of developing IBE

The ductal carcinoma in situ Score quantifies the risk of ipsilateral breast event and invasive IBE risk, complements both traditional clinical and pathologic factors, and helps provide a new clinical tool to improve the process of selecting individualized treatment for women with DCIS who meet the criteria, according to a study published May 2 in the Journal of the National Cancer Institute.

3 May 2013

Prosigna Breast Cancer Prognostic Gene Signature Assay predicts ROR in women with early-stage breast cancer

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced results from two studies that are featured in oral presentations this week at IMPAKT Breast Cancer Conference.

2 May 2013

Clinical study shows association between results of ChemoFx and RFS of cervical cancer patients

A clinical study reporting an association between the results of the ChemoFx chemoresponse assay and recurrence free survival of cervical cancer patients has been accepted for publication by Gynecologic Oncology.

30 Apr 2013

Targeted therapy prevents rare neurodevelopmental disorder seizures

Rapamycin treatment reduces seizure frequency and improves receptive language in patients with polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, or Pretzel syndrome, a study finds.

29 Apr 2013

Assay News and Research

Scientists identify new markers for obesity treatment

Chromatrap® ChIP assay kit enriches epigenetic marks from primary human tissue cells

Lab-based skin test eliminates risk of adverse reactions to new drugs, cosmetics

TSRI scientists devise new technique to find therapeutic antibodies

Novel multiplex immunoassay approach to capture HIV antibodies

FDA approves Tina-quant HbA1cDx assay for diagnosis of diabetes

Researchers use new analysis method to determine genes that result in cell death

Previstage GCC Colorectal Cancer Staging Test study to be presented at 2013 ASCO Annual Meeting

Researchers identify clue to explain the reversible memory loss caused by statins

New diagnostic test could help health officials monitor, prevent spread of H7N9 virus

Abbott receives CE Mark for ARCHITECT HbA1c test

Precision Therapeutics to present clinical data of ChemoFx chemoresponse assay at WAGO meeting

UCSF researchers find new genomic test to identify aggressive form of prostate cancer

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

Novel screening method for identifying inhibitors of EZH2 methyltransferase

Measurement variation influences gene expression profiles of breast cancer

Researchers find association between DCIS Score and risk of developing IBE

Prosigna Breast Cancer Prognostic Gene Signature Assay predicts ROR in women with early-stage breast cancer

Clinical study shows association between results of ChemoFx and RFS of cervical cancer patients

Targeted therapy prevents rare neurodevelopmental disorder seizures

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News